Prolonged Clinical Benefit with Futibatinib in a Patient with FGFR Inhibitor-Pretreated Fusion-Positive Intrahepatic Cholangiocarcinoma: Case Report

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2024 Jun 19

PMID 38895132

Authors

Paolo D dArienzo

Alan R MacDonald

Virjen Patel

Yuk T Ma

Rille Pihlak

Naureen Starling

Affiliations

Soon will be listed here.

Abstract

Multiple FGFR inhibitors have demonstrated significant activity in pretreated advanced fusion-positive intrahepatic cholangiocarcinoma. The irreversible pan-FGFR inhibitor futibatinib has the potential to overcome acquired resistance to ATP-competitive FGFR inhibitors in a subset of patients. We present a case of prolonged clinical benefit using FGFR inhibitors sequentially, initially an ATP-competitive inhibitor followed by futibatinib upon progression, for a total of 36 months of FGFR-targeting therapy. This case supports sequential FGFR-targeting therapies for fusion-positive cholangiocarcinoma, with futibatinib acting as rescue therapy after failure of ATP-competitive inhibitors.

References

Farouk Sait S, Gilheeney S, Bale T, Haque S, Dinkin M, Vitolano S . Debio1347, an Oral FGFR Inhibitor: Results From a Single-Center Study in Pediatric Patients With Recurrent or Refractory FGFR-Altered Gliomas. JCO Precis Oncol. 2021; 5. PMC: 8232545. DOI: 10.1200/PO.20.00444. View

Mok T, Camidge D, Gadgeel S, Rosell R, Dziadziuszko R, Kim D . Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020; 31(8):1056-1064. DOI: 10.1016/j.annonc.2020.04.478. View

Lau D, Jenkins L, Weickhardt A . Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy. Cancer Drug Resist. 2022; 2(3):568-579. PMC: 8992533. DOI: 10.20517/cdr.2019.42. View

Rizzo A . Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors. Medicina (Kaunas). 2021; 57(5). PMC: 8151905. DOI: 10.3390/medicina57050458. View

Abou-Alfa G, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R . Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020; 21(5):671-684. PMC: 8461541. DOI: 10.1016/S1470-2045(20)30109-1. View

Silverman I, Hollebecque A, Friboulet L, Owens S, Newton R, Zhen H . Clinicogenomic Analysis of -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib. Cancer Discov. 2020; 11(2):326-339. DOI: 10.1158/2159-8290.CD-20-0766. View

Kommalapati A, Tella S, Borad M, Javle M, Mahipal A . FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. Cancers (Basel). 2021; 13(12). PMC: 8231807. DOI: 10.3390/cancers13122968. View

Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau H . Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring / Aberrations: A Phase I Dose-Expansion Study. Cancer Discov. 2021; 12(2):402-415. PMC: 9762334. DOI: 10.1158/2159-8290.CD-21-0697. View

Goyal L, Shi L, Liu L, Fece de la Cruz F, Lennerz J, Raghavan S . TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019; 9(8):1064-1079. PMC: 6677584. DOI: 10.1158/2159-8290.CD-19-0182. View

10.

Rizzo A, Ricci A, Brandi G . Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opin Investig Drugs. 2020; 30(4):317-324. DOI: 10.1080/13543784.2021.1837774. View

11.

Aldea M, Hendriks L, Mezquita L, Jovelet C, Planchard D, Auclin E . Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression. J Thorac Oncol. 2019; 15(3):383-391. DOI: 10.1016/j.jtho.2019.11.024. View

12.

McSheehy P, Forster-Gross N, El Shemerly M, Bachmann F, Roceri M, Hermann N . The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo. Anticancer Drugs. 2023; 34(4):532-543. DOI: 10.1097/CAD.0000000000001469. View

13.

Rengan A, Denlinger C . Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib. J Natl Compr Canc Netw. 2022; 20(5):430-435. DOI: 10.6004/jnccn.2021.7121. View

14.

Vogel A, Bridgewater J, Edeline J, Kelley R, Klumpen H, Malka D . Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 34(2):127-140. DOI: 10.1016/j.annonc.2022.10.506. View

15.

Goyal L, Meric-Bernstam F, Hollebecque A, Valle J, Morizane C, Karasic T . Futibatinib for -Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med. 2023; 388(3):228-239. DOI: 10.1056/NEJMoa2206834. View

16.

Ramalingam S, Vansteenkiste J, Planchard D, Cho B, Gray J, Ohe Y . Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC. N Engl J Med. 2019; 382(1):41-50. DOI: 10.1056/NEJMoa1913662. View

17.

Lamarca A, Barriuso J, McNamara M, Valle J . Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. J Hepatol. 2020; 73(1):170-185. DOI: 10.1016/j.jhep.2020.03.007. View

18.

Javle M, Roychowdhury S, Kelley R, Sadeghi S, Macarulla T, Weiss K . Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021; 6(10):803-815. DOI: 10.1016/S2468-1253(21)00196-5. View

19.

Goyal L, Kongpetch S, Crolley V, Bridgewater J . Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat Rev. 2021; 95:102170. DOI: 10.1016/j.ctrv.2021.102170. View

20.

Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K . Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors. Cancer Res. 2020; 80(22):4986-4997. DOI: 10.1158/0008-5472.CAN-19-2568. View